⌘K

Login Start Free

Home/Filings/4/0001104659-18-023012

4//SEC Filing

Vaughn Victor 4

Accession 0001104659-18-023012

CIK 0001356576other

View on SEC.gov Company Profile

Filed

Apr 8, 8:00 PM ET

Accepted

Apr 9, 12:12 PM ET

Size

19.9 KB

Accession

0001104659-18-023012

Insider Transaction Report

Form 4

Period: 2018-04-05

SUPERNUS PHARMACEUTICALS INCSUPN

Senior Vice President of Sales

Transactions

Sale
Common Stock
2018-04-05$45.33/sh−26,250$1,189,899→ 9,344 total
Exercise/Conversion
Common Stock
2018-04-05$9.24/sh+15,000$138,600→ 24,344 total
Sale
Common Stock
2018-04-05$45.33/sh−15,000$679,943→ 9,344 total
Sale
Common Stock
2018-04-05$45.33/sh−18,750$849,928→ 9,344 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-05−26,250→ 8,750 total
Exercise: $9.13Exp: 2025-03-03→ Common Stock (26,250 underlying)
Exercise/Conversion
Common Stock
2018-04-05$9.13/sh+26,250$239,663→ 35,594 total
Exercise/Conversion
Common Stock
2018-04-05$12.98/sh+18,750$243,375→ 28,094 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-05−15,000→ 0 total
Exercise: $9.24Exp: 2024-01-21→ Common Stock (15,000 underlying)
Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-04-05−18,750→ 31,250 total
Exercise: $12.98Exp: 2026-03-01→ Common Stock (18,750 underlying)

Footnotes (5)

[F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.1500 to $45.9750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
[F3]The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted.
[F4]The option became exercisable in four equal installments beginning on March 3, 2016, which was the first anniversary of the date on which the option was granted.
[F5]The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted.

Documents

1 file

4
a4.xmlPrimary
4

Issuer

SUPERNUS PHARMACEUTICALS INC

CIK 0001356576

Entity typeother

Related Parties

1

filerCIK 0001567077

Filing Metadata

Form type: 4
Filed: Apr 8, 8:00 PM ET
Accepted: Apr 9, 12:12 PM ET
Size: 19.9 KB

View on SEC.gov